Keywords: HIV; HAART; serodiscordant couples; pregnancy; stigma
Received 14 December 2016; Accepted 27 December 2016; Published 8 March 2017
Copyright: © 2017 Fransen-dos Santos R and Guarinieri M; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Fransen-dos Santos R and Guarinieri M. Journal of the International AIDS Society 2017, 20(Suppl 1):21749 Read more
Key Populations and the Global Fund: Delivering Key Results explains why ending AIDS, TB and malaria will be impossible without addressing the needs of and working with key and vulnerable populations. It details the unique role the Global Fund has played to support and mobilize domestic resources for key populations, challenge human rights barriers to health and provide opportunities for these populations to participate in the development and implementation of programmes that affect them.
Global Fund Replenishment 2016: The Cost of Inaction demonstrates that inadequate investment in the Global Fund will threaten millions of lives and result in billions of dollars in additional costs. According to the report, failure to fully fund the global responses for AIDS, TB and malaria, including replenishing the Global Fund, over the next six years, will:
- Result in 21 million preventable AIDS deaths and 28 million preventable new HIV infections;
- Give rise to 45 million new TB infections and an additional 29 million people needing treatment;
- Jeopardize the potential to avert 3 million malaria cases and save 10 million lives.
Additionally, the Cost of Inaction report describes how simply maintaining current levels of investment could result in a rise of drug-resistant strains of HIV, TB and malaria that are even more costly to treat. For example, the number of people with HIV who will require more expensive second-line treatments – usually as a result of drug resistance – is estimated to double between 2014 and 2020.